Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Weight loss intervention improves quality of life in breast cancer survivors

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC